Bobae Kim - Mar 30, 2023 Form 3 Insider Report for Bellerophon Therapeutics, Inc. (BLPH)

Role
VP Reg. Affairs & Quality
Signature
/s/ Bobae Kim
Stock symbol
BLPH
Transactions as of
Mar 30, 2023
Transactions value $
$0
Form type
3
Date filed
4/3/2023, 05:46 PM
Next filing
May 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BLPH Common Stock 9.89K Mar 30, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BLPH Restricted Stock Units Mar 30, 2023 Common Stock 11K $0.00 Direct F1, F2
holding BLPH Stock Options (right to buy) Mar 30, 2023 Common Stock 133 $21.00 Direct F3
holding BLPH Stock Options (right to buy) Mar 30, 2023 Common Stock 266 $7.35 Direct F3
holding BLPH Stock Options (right to buy) Mar 30, 2023 Common Stock 1.2K $33.00 Direct F3
holding BLPH Stock Options (right to buy) Mar 30, 2023 Common Stock 1K $13.20 Direct F3
holding BLPH Stock Options (right to buy) Mar 30, 2023 Common Stock 1.17K $7.50 Direct F4
holding BLPH Stock Options (right to buy) Mar 30, 2023 Common Stock 50K $1.52 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents the contingent right to receive, upon vesting of the unit, one share of Bellerophon common stock. The restricted stock units are scheduled to vest on December 8, 2023, as long as the reporting person remains in the service of Bellerophon through the respective vesting date.
F2 Not Applicable.
F3 Fully vested and exercisable.
F4 This option was granted on September 26, 2019. This option vests in quarterly installments over a four-years period from the date of grant.
F5 This option vests as to 25% of the underlying shares on February 10, 2024 and the remaining options vest quarterly over a period of 3 years thereafter.